At the time of writing, Akero Therapeutics Inc [AKRO] stock is trading at $45.22, down -2.12%. An important factor to consider is whether the stock is rising or falling in short-term value. The AKRO shares have gain 4.05% over the last week, with a monthly amount drifted -5.69%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen started tracking the stock with Buy rating on August 04, 2025, and set its price target to $76. On January 30, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $63 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $72 on January 27, 2025. Citigroup initiated its recommendation with a Buy and recommended $65 as its price target on November 18, 2024. In a note dated September 19, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $69 on this stock.
For the past year, the stock price of Akero Therapeutics Inc fluctuated between $21.34 and $58.40. Currently, Wall Street analysts expect the stock to reach $72 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $45.22 at the most recent close of the market. An investor can expect a potential return of 59.22% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.25% with Operating Profit Margin at -80370.75%, Pretax Profit Margin comes in at -70989.75%, and Net Profit Margin reading is -70989.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.32 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Akero Therapeutics Inc [NASDAQ:AKRO] has a current ratio of 12.66. On the other hand, the Quick Ratio is 12.66, and the Cash Ratio is 3.65.
Transactions by insiders
Recent insider trading involved Young Jonathan, Chief Operating Officer, that happened on Sep 11 ’25 when 586.0 shares were sold. Chief Development Officer, Yale Catriona completed a deal on Sep 11 ’25 to sell 659.0 shares. Meanwhile, Chief Financial Officer White William Richard sold 659.0 shares on Sep 11 ’25.
